Open Access

CASE REPORT

Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy

Xie Ding^1,2,3,#, Xinfeng Liu^4,#, Cheng Dai⁵, Xiaoxiao Wang^1,2,3, Zhaopeng Zheng^2,3,*

1 The Second Clinical College, Zunyi Medical University, Zunyi, China
2 Department of Oncology, The People’s Hospital of QianNan, Duyun, China
3 Department of Oncology, Guizhou Provincial People’s Hospital, Guiyang, China
4 Department of Radiology, Guizhou Provincial People’s Hospital, Guiyang, China
5 Department of Gynecology, Guizhou Provincial People’s Hospital, Guiyang, China

* Corresponding Author: Zhaopeng Zheng. Email:
# These authors contributed equally to this work as the first author

Oncology Research 2026, 34(5), 37 https://doi.org/10.32604/or.2026.071213

Received 02 August 2025; Accepted 03 February 2026; Issue published 22 April 2026

Abstract

Background: Immunotherapy has markedly reshaped the therapeutic landscape for patients with postoperative progression and metastasis. As a programmed death-1 (PD-1) inhibitor, camrelizumab has been proven to exhibit both efficacy and safety in the treatment of advanced dMMR solid tumors. Case Description: A 58-year-old female patient with neuroendocrine carcinoma of the endometrium (NECE) who was treated with camrelizumab coupled with chemotherapy, subsequent maintenance monotherapy with camrelizumab, and adjuvant pelvic local radiotherapy. Up to December 2024, the patient has survived 28 months since treatment, with 26 months free from disease progression, and the assessment indicated a status of clinical complete response (cCR). Conclusion: The combined regimen achieves notable efficacy and is free of unexpected adverse effects, with only a radiotherapy-related pelvic insufficiency fracture (PIF) report.

---

Keywords

---

Supplementary Material

Supplementary Material File

---